Evidence and Managed Care Considerations for the Use of Novel Immunotherapies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

This activity was originally broadcast in conjunction with the 2023 AMCP Annual Meeting.

Program Description

Diffuse large B-cell lymphoma (DLBCL) is an aggressive subtype of non-Hodgkin lymphoma (NHL). Despite standard-of-care immunotherapy, 30% to 40% of patients continue to experience relapse with poor prognosis or are refractory to frontline treatment. With limited approved treatment options in the relapsed/refractory (R/R) setting, there is an important opportunity for managed care pharmacists to remain informed about recently developed therapies, including chimeric antigen receptor (CAR) T-cell therapy, antibody-drug conjugates (ADCs), and the investigational T-cell engaging bispecific antibodies (BsAbs), as they develop clinical pathways for DLBCL. This program will review the distinctive features of CAR T-cell therapy that differentiate it from ADCs and BsAbs, with special consideration for patient-specific factors that influence treatment selection. Managed care strategies to address health care disparities, access to care, and affordability will also be discussed.

Target audience: Oncology and managed care pharmacists

Type of activity: Application
Release date: April 7, 2023
Expiration date: April 7, 2024

Time to complete activity: 1.5 hours

Learner level: Intermediate
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Compare the role of antibody-drug conjugates and chimeric antigen receptor (CAR) T-cell therapy in the treatment paradigm of relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and the emerging data on the utility of bispecific antibodies.
• Examine recent clinical data, current treatment guidelines, and their impact to formulary decisions for the treatment of R/R DLBCL.
• Explore opportunities to facilitate access and improve safety and supportive care for patients with R/R DLBCL through appropriate assessment of patients and their treatment regimens.

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-23-128-H01-P. The activity is available for CE credit through April 7, 2024.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Bernard Marini, PharmD, BCOP, has the following relevant financial relationship with a commercial interest to disclose:

• Consultant: Servier Pharmaceuticals

Zahra Mahmoudjafari, PharmD, MBA, BCOP, has the following relevant financial relationships with commercial interests to disclose:

• Consultant: Bristol Myers Squibb, Incyte, Merck, Seagen, Sanofi
• Speaker’s Bureau: Omeros

Pharmacy Times Continuing Education™ Planning Staff: Jim Palatine, RPh, MBA; Amy H. Seung, PharmD, BCOP, FHOPA, CHCP; Evelina Kolychev, PharmD, BCOP; Kylie Ferrentino; Susan Pordon; Brianna Winters; and Chloe Taccetta have no financial relationships with commercial interests to disclose.

Anonymous peer reviewers have been used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms